fluprednisolone has been researched along with Cataract in 8 studies
Fluprednisolone: A synthetic glucocorticoid with anti-inflammatory properties.
Cataract: Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Difluprednate administered twice a day was at least as effective as prednisolone acetate administered 4 times a day for inflammatory treatment after cataract surgery." | 9.51 | Difluprednate 0.05% twice a day vs prednisolone acetate 1% 4 times a day for cataract postsurgical inflammation treatment: noninferiority trial. ( Del Papa, M; Ferroni, C; Ferroni, V; Idiart, C; Kaufer, R; Marino, F; Masseroni, M; Nuñez, M; Passerini, MS; Valvecchia, G; Zaldívar, R, 2022) |
| "To evaluate the clinical effect of topical difluprednate in pediatric patients for treatment of noninfectious uveitis." | 7.78 | Efficacy and potential complications of difluprednate use for pediatric uveitis. ( Herlihy, E; Ongchin, S; Slabaugh, MA; van Gelder, RN, 2012) |
| "To report the effects of twice-daily difluprednate in a child with pars planitis (PP)." | 7.77 | Effects of twice-daily topical difluprednate 0.05% emulsion in a child with pars planitis. ( Chheda, LV; Kurz, DE; Kurz, PA, 2011) |
| " Safety included evaluation of adverse events." | 6.82 | Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study. ( Gedif, K; Lambert, SR; Markwardt, K; O'Halloran, H; Plager, DA; Roarty, J; VanderVeen, D; Wilson, ME, 2016) |
| "Difluprednate administered twice a day was at least as effective as prednisolone acetate administered 4 times a day for inflammatory treatment after cataract surgery." | 5.51 | Difluprednate 0.05% twice a day vs prednisolone acetate 1% 4 times a day for cataract postsurgical inflammation treatment: noninferiority trial. ( Del Papa, M; Ferroni, C; Ferroni, V; Idiart, C; Kaufer, R; Marino, F; Masseroni, M; Nuñez, M; Passerini, MS; Valvecchia, G; Zaldívar, R, 2022) |
| "To evaluate the clinical effect of topical difluprednate in pediatric patients for treatment of noninfectious uveitis." | 3.78 | Efficacy and potential complications of difluprednate use for pediatric uveitis. ( Herlihy, E; Ongchin, S; Slabaugh, MA; van Gelder, RN, 2012) |
| "To report the effects of twice-daily difluprednate in a child with pars planitis (PP)." | 3.77 | Effects of twice-daily topical difluprednate 0.05% emulsion in a child with pars planitis. ( Chheda, LV; Kurz, DE; Kurz, PA, 2011) |
| " Safety included evaluation of adverse events." | 2.82 | Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study. ( Gedif, K; Lambert, SR; Markwardt, K; O'Halloran, H; Plager, DA; Roarty, J; VanderVeen, D; Wilson, ME, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Valvecchia, G | 1 |
| Kaufer, R | 1 |
| Ferroni, C | 1 |
| Zaldívar, R | 1 |
| Masseroni, M | 1 |
| Idiart, C | 1 |
| Ferroni, V | 1 |
| Marino, F | 1 |
| Nuñez, M | 1 |
| Del Papa, M | 1 |
| Passerini, MS | 1 |
| Moshirfar, M | 1 |
| Somani, AN | 1 |
| Motlagh, MN | 1 |
| Ronquillo, YC | 1 |
| Wilson, ME | 2 |
| O'Halloran, H | 2 |
| VanderVeen, D | 2 |
| Roarty, J | 2 |
| Plager, DA | 2 |
| Markwardt, K | 1 |
| Gedif, K | 1 |
| Lambert, SR | 2 |
| Kaur, S | 1 |
| Sukhija, J | 1 |
| Kurz, PA | 1 |
| Chheda, LV | 1 |
| Kurz, DE | 1 |
| Slabaugh, MA | 1 |
| Herlihy, E | 1 |
| Ongchin, S | 1 |
| van Gelder, RN | 1 |
| HAVRE, DC | 1 |
1 review available for fluprednisolone and Cataract
| Article | Year |
|---|---|
Management of cataract in the setting of uveitis: a review of the current literature.
Topics: Administration, Ophthalmic; Cataract; Cataract Extraction; Dexamethasone; Drug Implants; Flupredniso | 2020 |
2 trials available for fluprednisolone and Cataract
| Article | Year |
|---|---|
Difluprednate 0.05% twice a day vs prednisolone acetate 1% 4 times a day for cataract postsurgical inflammation treatment: noninferiority trial.
Topics: Cataract; Eye Diseases; Fluprednisolone; Humans; Inflammation; Phacoemulsification; Postoperative Co | 2022 |
Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study.
Topics: Administration, Topical; Aphakia, Postcataract; Cataract; Cataract Extraction; Child, Preschool; Dou | 2016 |
5 other studies available for fluprednisolone and Cataract
| Article | Year |
|---|---|
Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study.
Topics: Anti-Inflammatory Agents; Cataract; Cataract Extraction; Child; Double-Blind Method; Fluprednisolone | 2017 |
Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study.
Topics: Anti-Inflammatory Agents; Cataract; Cataract Extraction; Child; Double-Blind Method; Fluprednisolone | 2017 |
Effects of twice-daily topical difluprednate 0.05% emulsion in a child with pars planitis.
Topics: Administration, Topical; Cataract; Child; Emulsions; Fluprednisolone; Glucocorticoids; Humans; Male; | 2011 |
Efficacy and potential complications of difluprednate use for pediatric uveitis.
Topics: Administration, Topical; Adolescent; Aqueous Humor; Cataract; Child; Female; Fluprednisolone; Glucoc | 2012 |
CATARACTS IN CHILDREN ON LONG-TERM CORTICOSTEROID THERAPY.
Topics: Adolescent; Adrenal Cortex Hormones; Cataract; Child; Chloroquine; Cyclophosphamide; Drug Therapy; F | 1965 |